• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5077518)   Today's Articles (215)
For: Yong X, Wen A, Liu X, Liu H, Liu YP, Li N, Hu T, Chen Y, Wang M, Wang L, Dai X, Huang J, Li J, Shen H. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus. Clin Drug Investig 2015;36:195-202. [DOI: 10.1007/s40261-015-0366-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Number Cited by Other Article(s)
1
Cai L, Zhao Y, Li Z, Xiao L, Wu Y, Wang S, Liu Q, Ye Y, Guo Y, Zhang D. A Human Engineered Heart Tissue-Derived Lipotoxic Diabetic Cardiomyopathy Model Revealed Early Benefits of Empagliflozin. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2025:e03173. [PMID: 40433797 DOI: 10.1002/advs.202503173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2025] [Revised: 04/21/2025] [Indexed: 05/29/2025]
2
Sharma S, Kumar S, Gupta J, Mittal A, Khurana N. Design, synthesis and biological evaluation of non-glucosidal based 1,3,4-thiadiazoles as SGLT-2 inhibitors. Future Med Chem 2025;17:409-423. [PMID: 39935011 PMCID: PMC11834423 DOI: 10.1080/17568919.2025.2463869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Accepted: 01/27/2025] [Indexed: 02/13/2025]  Open
3
Yan H, Wang W, Li Y, Qi Y, Lu R, Zhou Y, Zhang W, Liu S, Pang H, Fang Y, Li Z, Wang J, Jiang M, Pu J, Gu L, Fang W. Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open 2024;14:e087617. [PMID: 39191464 PMCID: PMC11404262 DOI: 10.1136/bmjopen-2024-087617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Accepted: 08/05/2024] [Indexed: 08/29/2024]  Open
4
Ding L, Yang L, Ren D, Gao X, Zhang J, Liu M, Sun L, Diao Q, Feng S, Wen A, Wang J. Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Proline Henagliflozin in Chinese Subjects with Varying Degrees of Liver Dysfunction. J Clin Pharmacol 2024;64:1015-1022. [PMID: 38686508 DOI: 10.1002/jcph.2437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 03/13/2024] [Indexed: 05/02/2024]
5
Wang Y, Jiang C, Dong X, Chen M, Gu Q, Zhang L, Fu Y, Pan T, Bi Y, Song W, Xu J, Lu W, Sun X, Ye Z, Zhang D, Peng L, Lin X, Dai W, Wang Q, Yang W. Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab 2024;26:2774-2786. [PMID: 38618970 DOI: 10.1111/dom.15596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/25/2023] [Revised: 03/25/2024] [Accepted: 03/25/2024] [Indexed: 04/16/2024]
6
Chen Q, Yu C, Wu Q, Song R, Liu Y, Feng S, Yu C, Jia J. Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers. Drug Des Devel Ther 2024;18:1855-1864. [PMID: 38828023 PMCID: PMC11144404 DOI: 10.2147/dddt.s433377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 04/29/2024] [Indexed: 06/05/2024]  Open
7
Ding L, Liu S, Yan H, Li Z, Zhou Y, Pang H, Lu R, Zhang W, Che M, Wang L, Wang Q, Fang W, Zhang M, Che X, Gu L. Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes. Clin Pharmacokinet 2023;62:1581-1587. [PMID: 37713096 DOI: 10.1007/s40262-023-01300-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/25/2023] [Indexed: 09/16/2023]
8
Liu Y, Huyan X, Zhang Q, Qing H, Zhang Q, Wang X, Li Y, Liu Z, Hu W. Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers. Clin Pharmacol Drug Dev 2022;12:376-384. [PMID: 36408821 DOI: 10.1002/cpdd.1193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 10/02/2022] [Indexed: 11/22/2022]
9
Huang Y, Liu R, Wang Y, Liu G, Wang C, Chen X, Jia Y, Shen J. Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers. Clin Ther 2022;44:945-956. [PMID: 35778161 DOI: 10.1016/j.clinthera.2022.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/03/2022] [Accepted: 06/03/2022] [Indexed: 11/03/2022]
10
Que L, Huang K, Xiang X, Ding Y, Chu N, He Q. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects. J Clin Pharm Ther 2022;47:1225-1231. [PMID: 35362180 DOI: 10.1111/jcpt.13659] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 03/05/2022] [Accepted: 03/16/2022] [Indexed: 12/20/2022]
11
Chen ZD, Chen Q, Zhu YT, Zhang YF, Zhan Y, Chen XF, Liang X, Jia JY, Yu C, Liu HY, Zou JJ, Liu YM, Zhong DF. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers. Clin Ther 2021;43:e264-e273. [PMID: 34366153 DOI: 10.1016/j.clinthera.2021.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 06/23/2021] [Accepted: 07/05/2021] [Indexed: 10/20/2022]
12
Lu J, Fu L, Li Y, Geng J, Qin L, Li P, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Lu W, Guo Y, Zhang Y, Liu H, Zhang T, Zou J. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab 2021;23:1111-1120. [PMID: 33417292 DOI: 10.1111/dom.14314] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 12/23/2020] [Accepted: 01/04/2021] [Indexed: 02/05/2023]
13
Zhang YF, Liu YM, Yu C, Wang YT, Zhan Y, Liu HY, Zou JJ, Jia JY, Chen Q, Zhong DF. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration. Clin Ther 2021;43:396-409. [PMID: 33454124 DOI: 10.1016/j.clinthera.2020.12.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 12/06/2020] [Accepted: 12/12/2020] [Indexed: 12/28/2022]
14
Chen Z, Li L, Zhan Y, Zhang Y, Liu H, Zou J, Zhong D. Characterization and quantitative determination of henagliflozin metabolites in humans. J Pharm Biomed Anal 2020;192:113632. [PMID: 33069964 DOI: 10.1016/j.jpba.2020.113632] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Revised: 09/02/2020] [Accepted: 09/10/2020] [Indexed: 12/11/2022]
15
Johansson KS, Sonne DP, Knop FK, Christensen MB. What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. Expert Opin Drug Discov 2020;15:1253-1265. [DOI: 10.1080/17460441.2020.1791078] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
16
Adeghate E, Mohsin S, Adi F, Ahmed F, Yahya A, Kalász H, Tekes K, Adeghate EA. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. Expert Opin Investig Drugs 2019;28:811-820. [PMID: 31402716 DOI: 10.1080/13543784.2019.1655539] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA